ACRUX Ltd

AU:ACR Australia Biotechnology
Market Cap
$3.05 Million
AU$4.93 Million AUD
Market Cap Rank
#34021 Global
#1214 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.03
All Time High
AU$0.83
Categories
Companies in Australia Biotechnology
About

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more

ACRUX Ltd (ACR) - Net Assets

Latest net assets as of June 2025: AU$1.02 Million AUD

Based on the latest financial reports, ACRUX Ltd (ACR) has net assets worth AU$1.02 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.22 Million) and total liabilities (AU$6.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$1.02 Million
% of Total Assets 14.16%
Annual Growth Rate -9.52%
5-Year Change -94.46%
10-Year Change -97.67%
Growth Volatility 71.79

ACRUX Ltd - Net Assets Trend (2001–2025)

This chart illustrates how ACRUX Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for ACRUX Ltd (2001–2025)

The table below shows the annual net assets of ACRUX Ltd from 2001 to 2025.

Year Net Assets Change
2025-06-30 AU$1.02 Million -68.77%
2024-06-30 AU$3.28 Million -62.33%
2023-06-30 AU$8.70 Million -4.33%
2022-06-30 AU$9.09 Million -50.79%
2021-06-30 AU$18.47 Million +43.75%
2020-06-30 AU$12.85 Million -41.43%
2019-06-30 AU$21.94 Million -26.81%
2018-06-30 AU$29.97 Million -31.77%
2017-06-30 AU$43.92 Million +0.08%
2016-06-30 AU$43.89 Million +8.03%
2015-06-30 AU$40.62 Million -3.40%
2014-06-30 AU$42.06 Million -10.04%
2013-06-30 AU$46.75 Million -11.96%
2012-06-30 AU$53.10 Million +16.17%
2011-06-30 AU$45.71 Million -43.19%
2010-06-30 AU$80.47 Million +157.72%
2009-06-30 AU$31.22 Million -18.07%
2008-06-30 AU$38.11 Million +108.86%
2007-06-30 AU$18.25 Million -11.35%
2006-06-30 AU$20.58 Million -30.18%
2005-06-30 AU$29.48 Million +250.60%
2004-06-30 AU$8.41 Million -27.91%
2003-06-30 AU$11.66 Million -33.29%
2002-06-30 AU$17.49 Million +55.04%
2001-06-30 AU$11.28 Million --

Equity Component Analysis

This analysis shows how different components contribute to ACRUX Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 12623200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$118.22 Million 11556.01%
Other Comprehensive Income AU$9.04 Million 883.38%
Total Equity AU$1.02 Million 100.00%

ACRUX Ltd Competitors by Market Cap

The table below lists competitors of ACRUX Ltd ranked by their market capitalization.

Company Market Cap
Globalink Investment Inc
NASDAQ:GLLI
 		$2.16 Million
Argo Blockchain PLC
PINK:ARBKF
 		$2.16 Million
VULCAN MATERIALS - Dusseldorf Stock Exchang
DU:VMC
 		$2.16 Million
SONOVA HLDG N - Dusseldorf Stock Exchang
DU:PHBN
 		$2.16 Million
Tokyo Electron Limited
MU:TKY
 		$2.16 Million
SCL_S.C.L. MOTOR PART
BK:SCL
 		$2.16 Million
MARKET VECTR RETAIL
BE:VEFW
 		$2.16 Million
Weed Inc
OTCQB:BUDZ
 		$2.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ACRUX Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,276,000 to 1,023,000, a change of -2,253,000 (-68.8%).
  • Net loss of 5,945,000 reduced equity.
  • New share issuances of 3,376,000 increased equity.
  • Other comprehensive income increased equity by 486,000.
  • Other factors decreased equity by 170,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-5.95 Million -581.13%
Share Issuances AU$3.38 Million +330.01%
Other Comprehensive Income AU$486.00K +47.51%
Other Changes AU$-170.00K -16.62%
Total Change AU$- -68.77%

Book Value vs Market Value Analysis

This analysis compares ACRUX Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.13x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.07x to 4.13x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-06-30 AU$0.18 AU$0.01 x
2003-06-30 AU$0.12 AU$0.01 x
2004-06-30 AU$0.08 AU$0.01 x
2005-06-30 AU$0.24 AU$0.01 x
2006-06-30 AU$0.15 AU$0.01 x
2007-06-30 AU$0.13 AU$0.01 x
2008-06-30 AU$0.24 AU$0.01 x
2009-06-30 AU$0.20 AU$0.01 x
2010-06-30 AU$0.50 AU$0.01 x
2011-06-30 AU$0.28 AU$0.01 x
2012-06-30 AU$0.32 AU$0.01 x
2013-06-30 AU$0.28 AU$0.01 x
2014-06-30 AU$0.25 AU$0.01 x
2015-06-30 AU$0.24 AU$0.01 x
2016-06-30 AU$0.26 AU$0.01 x
2017-06-30 AU$0.26 AU$0.01 x
2018-06-30 AU$0.18 AU$0.01 x
2019-06-30 AU$0.13 AU$0.01 x
2020-06-30 AU$0.08 AU$0.01 x
2021-06-30 AU$0.08 AU$0.01 x
2022-06-30 AU$0.03 AU$0.01 x
2023-06-30 AU$0.03 AU$0.01 x
2024-06-30 AU$0.01 AU$0.01 x
2025-06-30 AU$0.00 AU$0.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ACRUX Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -581.13%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -499.58%
  • • Asset Turnover: 0.16x
  • • Equity Multiplier: 7.06x
  • Recent ROE (-581.13%) is below the historical average (-38.13%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -17.99% -574.45% 0.03x 1.05x AU$-4.89 Million
2003 -0.09% -1.34% 0.06x 1.10x AU$-1.17 Million
2004 0.04% 0.09% 0.33x 1.16x AU$-835.54K
2005 0.08% 0.88% 0.09x 1.05x AU$-2.92 Million
2006 -48.29% -1922.63% 0.02x 1.13x AU$-12.00 Million
2007 -43.08% -271.32% 0.14x 1.12x AU$-9.68 Million
2008 -13.19% -111.79% 0.11x 1.08x AU$-8.84 Million
2009 -24.71% -1187.08% 0.02x 1.12x AU$-10.84 Million
2010 57.85% 84.79% 0.66x 1.04x AU$38.51 Million
2011 125.02% 63.78% 1.52x 1.29x AU$52.58 Million
2012 13.92% 84.02% 0.15x 1.10x AU$2.08 Million
2013 14.81% 44.54% 0.29x 1.13x AU$2.25 Million
2014 66.50% 51.93% 1.01x 1.27x AU$23.76 Million
2015 27.40% 43.87% 0.52x 1.19x AU$7.07 Million
2016 29.58% 45.46% 0.54x 1.22x AU$8.59 Million
2017 -0.55% -1.02% 0.51x 1.08x AU$-4.64 Million
2018 -47.32% -413.23% 0.11x 1.08x AU$-17.18 Million
2019 -37.95% -1319.33% 0.03x 1.11x AU$-10.52 Million
2020 -73.71% -755.87% 0.07x 1.44x AU$-10.76 Million
2021 -68.37% -944.58% 0.06x 1.31x AU$-14.48 Million
2022 -108.18% -572.08% 0.11x 1.68x AU$-10.74 Million
2023 -8.79% -9.06% 0.59x 1.64x AU$-1.63 Million
2024 -177.05% -113.93% 0.57x 2.74x AU$-6.13 Million
2025 -581.13% -499.58% 0.16x 7.06x AU$-6.05 Million

Industry Comparison

This section compares ACRUX Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $33,407,963
  • Average return on equity (ROE) among peers: -65.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ACRUX Ltd (ACR) AU$1.02 Million -17.99% 6.06x $2.16 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million